The press release contains forward-looking statements regarding the use of funding proceeds, expansion of product distribution, acceleration of initiatives in liquid biopsy and SNP detection, use of the Company’s liquid biopsy tests by laboratories, capital resources and runway needed to advance the Company’s products and markets, increased sales in the near-term, flexibility in managing the Company’s balance sheet, anticipation of business expansion, and benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages.